360° SearchNetwork Hot Spots Trends Time Series

Degludec

Type: Product

Name: Degludec

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Europe must pay its way for innovation: Novo chief

Novo Nordisk's chief executive Lars Rebien Sorensen has accused politicians in some European countries of making empty promises to their populations in terms of access to innovative drugs and called for more harmonisation of regulatory systems across ... [Published Pharma Times - May 16 2013]

Entities: Insulin, Degludec, Invention

First reported May 11 2013 - Updated May 11 2013 - 1 reports

AACE: Degludec Shows Efficacy in Type 1 Diabetes

Type 1 diabetes patients had lower rates of nocturnal hypoglycemia with once-daily doses of insulin degludec versus similar doses of insulin glargine....According to Helena Rodbard, MD, a private practice endocrinologist in Washington, D.C., and past ... [Published Diabetes in Control - May 11 2013]

Entities: Degludec, hypoglycemia, Insulin

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Degludec Shows Efficacy in Type 1 Diabetes

http://www.for-diabetes.com/degludec-shows-efficacy-in-type-1-diabetes Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse PlannerPHOENIX — ... [Published Now Public - May 08 2013]

Entities: Degludec, Perelman School of Medicine, hypoglycemia

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Quality of Life Greatly Affected by Hypoglycemia (CME/CE)

Earn Free CME Credits by reading the latest medical newsin your specialty.Sign UpReviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of PennsylvaniaFor best viewing, click the bottom right corner for full ... [Published MedPage Today - May 07 2013]

Entities: hypoglycemia, Patient, Diabetes Type I

First reported May 05 2013 - Updated May 06 2013 - 1 reports

Glucose Variance Tied to Hypoglycemia Risk

Greater variability in fasting blood glucose may pose a greater risk of hypoglycemia for type 1 and type 2 diabetics.The study suggests that reducing day-to-day, within-subject variability in fasting blood glucose in patients with diabetes may lower the ... [Published MedPage Today - May 05 2013]

Entities: hypoglycemia, Glucose, Fasting

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Degludec Shows Efficacy in Type 1 Diabetes

Note that this meta-analysis of randomized trials demonstrates that insulin degludec has more favorable nocturnal hypoglycemia rates than insulin glargine in type 1 diabetics.Be aware that no differences in terms of hemoglobin A1C or overall glucose control ... [Published MedPage Today - May 03 2013]

Entities: Degludec, Insulin, hypoglycemia

First reported May 01 2013 - Updated May 02 2013 - 3 reports

Sanofi SA

US launch of Novo’s new insulin delayed

COPENHAGEN: Denmark’s Novo Nordisk could see the US launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.The world’s biggest insulin producer was dealt ... [Published The Gulf Today - May 02 2013]

Entities: Tresiba, Insulin, Sanofi SA, Drugs

First reported May 01 2013 - Updated May 01 2013 - 1 reports

UPDATE 1-Novo lifts sales target after profit tops forecasts

7:18am BST* Q1 EBIT 7.6 bln DKK vs 7.39 bln forecast* Q1 sales 20.0 bln, exceeding forecasts* Raises 2013 full-year sales growth guidance* Sees Tresiba cardio vascular trial completion in 4-6 yrs (Adds details, background, quotes)COPENHAGEN, May 1 (Reuters) ... [Published Reuters UK - May 01 2013]

Entities: Insulin, Tresiba, Lars Rebien Sørensen, Degludec, Victoza

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Top 5 Most Surprising Pharma Regulatory Agency Rejections

Following the CHMP’s recent negative opinion of Pfizer’s Xeljanz, I thought I’d take a look at some of the regulatory agency decisions that have taken some people by surprise over the years.Xeljanz – Rejected by : Committee for Medicinal Products for ... [Published Terrapinn - Apr 29 2013]

Entities: FDA Food & Drug Administration, Contrave, Xeljanz, Drugs, Fycompa

First reported Apr 27 2013 - Updated Apr 29 2013 - 1 reports

New treatment for diabetes is now available

A new once-daily basal insulin for adult patients with type 1 and type 2 diabetes is available in the UK as a new treatment option.Insulin degludec (Tresiba) can be administered at any time of the day and it is the first insulin to offer people with diabetes ... [Published Geriatric Medicine - Apr 27 2013]

Entities: Insulin, hypoglycemia, Diabetes, Degludec

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Insulin Degludec rejected for use within NHS Scotland

A new form of insulin treatment for people with diabetes has been turned down for NHS use in Scotland due to cost issues.Tresiba (Insulin Degludec) is an ultra-long-acting new-generation insulin that has duration of action beyond 42 hours, meaning patients ... [Published Diabetes.co.uk - Apr 24 2013]

Entities: Insulin, Degludec, NHS, Scotland, Tresiba

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Vigilance needed over insulin degludec strength

Vigilance by pharmacists and other healthcare professionals will be needed to avoid medication errors occurring with the newly launched insulin analogue insulin degludec (Tresiba), the Drug and Therapeutics Bulletin has warned.The April DTB says that ... [Published PJ Online - Apr 15 2013]

Entities: Degludec, Insulin, Tresiba, Therapeutics

Quotes

...M Benjamin, MD, FACP, Director of Healthcare Quality at Baystate Medical Center and assistant professor at Tufts University School of Medicine, "Judicious use of SMBG data can help to improve glycemic control, select an anti-diabetic regimen, and provide powerful feedback to patients wishing to improve metabolic control." In 2008, the ADA concluded and published in its Standard of Medical Care, that blood glucose monitoring helps in the planning of meals, activities, and...

LabStyle Innovations - Glucose Monitoring For The Mobile Age [Published Seeking Alpha - May 15 2013]

Rodbard added that, these results confirm that, "insulin degludec is a well-tolerated and effective basal insulin choice for patients with type 1 diabetes across the spectrum of insulin requirements."

AACE: Degludec Shows Efficacy in Type 1 Diabetes [Published Diabetes in Control - May 11 2013]

...have always suspected that severe hypoglycemia had some effect on patients but we didn't have that information until now," he told MedPage Today. "We did not realize that these very rare occurrences impacted patients across multiple domains of quality of life."

Quality of Life Greatly Affected by Hypoglycemia (CME/CE) [Published MedPage Today - May 07 2013]

"Reducing day-to-day, within-subject variability in fasting blood glucose in patients with diabetes may lower the incidence of hypoglycemia" Bode said

Glucose Variance Tied to Hypoglycemia Risk [Published MedPage Today - May 05 2013]

More Content

sort by: Date \| Relevance
Europe must pay its way for innovation: Novo chief [Published Pharma Times - May 16 2013]
LabStyle Innovations - Glucose Monitoring For T... [Published Seeking Alpha - May 15 2013]
AACE: Degludec Shows Efficacy in Type 1 Diabetes [Published Diabetes in Control - May 11 2013]
Degludec Shows Efficacy in Type 1 Diabetes [Published Now Public - May 08 2013]
Quality of Life Greatly Affected by Hypoglycemi... [Published MedPage Today - May 07 2013]
Glucose Variance Tied to Hypoglycemia Risk [Published MedPage Today - May 05 2013]
Degludec Shows Efficacy in Type 1 Diabetes [Published MedPage Today - May 03 2013]
US launch of Novo’s new insulin delayed [Published The Gulf Today - May 02 2013]
Novo Nordisk's Q1 Profit Up 28 Percent [Published PharmaceuticalProcessing - May 01 2013]
Very strong quarter for Novo despite Tresiba se... [Published Pharma Times - May 01 2013]
UPDATE 2-U.S. launch of Novo's new insulin face... [Published Reuters - May 01 2013]
UPDATE 1-Novo lifts sales target after profit t... [Published Reuters UK - May 01 2013]
Interview: Peter Meeus, Novo Nordisk [Published PMLive - Apr 30 2013]
Top 5 Most Surprising Pharma Regulatory Agency ... [Published Terrapinn - Apr 29 2013]
New treatment for diabetes is now available [Published Geriatric Medicine - Apr 27 2013]
Insulin Degludec rejected for use within NHS Sc... [Published Diabetes.co.uk - Apr 24 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Yahoo! Finance - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
BB BIOTECH AG : Biotech sector maintains upward... [Published Investegate - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]
Vigilance needed over insulin degludec strength [Published PJ Online - Apr 15 2013]
Novo Nordisk lancerer Tresiba® (insulin deglude... [Published Novo Nordisk A/S - Press Releases - Mar 04 2013]
Infinata’s BioPharm Insight Releases its Cataly... [Published PRWeb - Feb 26 2013]
Novo Nordisk to launch new diabetes therapy in ... [Published PBR - News - Feb 15 2013]
Novo Nordisk to launch diabetic drug, Tresiba i... [Published PharmaBiz - Feb 14 2013]
MannKind Earnings Call Insights: Partnership St... [Published Wall St. Cheat Sheet - Feb 12 2013]
US FDA seeks additional data from Novo Nordisk'... [Published PharmaBiz - Feb 12 2013]
FDA Turns Down Long-Acting Insulins [Published MedPageToday.com - medical news plus CME for ph ... - Feb 11 2013]
Sticking Point: FDA Rejects Novo Nordisk Insulin [Published Pharmalot - Feb 11 2013]

Blogs

sort by: Date \| Relevance
Novo Nordisk to launch new diabetes therapy in ... [Published PBR - News - Feb 15 2013] Novo Nordisk has received an approval of the price from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labour and Welfare, and is set to launch Tresiba (insulin degludec) in Japan. ...
MannKind Earnings Call Insights: Partnership St... [Published Wall St. Cheat Sheet - Feb 12 2013] MannKind Corporation ( NASDAQ:MNKD ) recently reported its fourth quarter earnings and discussed the following topics in its earnings conference call. Partnership Status Matthew Luchini – Piper Jaffray: This is Matthew on for Ian. Thanks for taking ...
Sticking Point: FDA Rejects Novo Nordisk Insulin [Published Pharmalot - Feb 11 2013] In a huge setback to Novo Nordisk, the FDA has rejected its new Tresiba insulin and wants a cardiovascular outcomes trial before a new review can be completed, a move that is widely expected to delay approval for at least two years. The rejection comes ...

Press Releases

sort by: Date \| Relevance
Novo Nordisk lancerer Tresiba® (insulin deglude... [Published Novo Nordisk A/S - Press Releases - Mar 04 2013]
Paid Diabetes Clinical Trial Now Enrolling at A... [Published PR.com Press Releases - Jan 29 2013]
Novo Nordisk A/S: Tresiba® (insulin degludec) o... [Published GlobeNewswire: Advertising News - Jan 21 2013]
Novo Nordisk A/S: Ryzodeg(R) (insulin degludec/... [Published Marketwire - Breaking News Releases - Dec 25 2012]
Novo Nordisk A/S: Ryzodeg® (insulin degludec/in... [Published GlobeNewswire: Acquisitions News - Dec 25 2012]